Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

RARE PHOTOS: 2 | Vintage Vibes

Regeneron Pharmaceuticals Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).

Benzinga

3 Biotech Stocks Set to Revolutionize Medicine

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry’s expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read…

StockNews.com

3 Biotech Stocks That Could Deliver Big Gains

The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of new therapeutics, and increased R&D spending on treatments for new and rare diseases. Hence, investors should consider strong biotech stocks such as Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which could deliver big…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

How Is Regeneron Pharmaceuticals' Stock Performance Compared to Other Biotechnology Stocks?

Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts are optimistic about the stock’s outlook.

Barchart

Plunge into Profits With These 3 Biotech Stocks

The biotech industry's robust growth potential is driven by substantial pharma research and development, swift technological advancements, and lucrative government support. Given this backdrop, quality biotech stocks ProQR Therapeutics N.V. (PRQR), Regeneron Pharmaceuticals (REGN), and Corcept Therapeutics (CORT) could be solid buys now. Read on….

StockNews.com

Regeneron surpasses Q4 revenue expectations with strong results

Regeneron Pharmaceuticals surpasses expectations with strong fourth-quarter revenue, boosting investor confidence in the company's performance.

Top News

Read news from The Economist, FT, and more,
with one subscription

Regeneron Pharmaceuticals (REGN) Earnings Analysis -- Should Investors Brace for Impact?

Regeneron Pharmaceuticals (REGN) has an impressive revenue and earnings surprise history. So, as the company gears up to post its third-quarter report, is REGN the right pick? Read on.

StockNews.com

3 Biotech Stocks With 'A' POWR Ratings

The biotech industry is poised for significant growth due to the rising orphan drug formulations and the adoption of emerging technologies. Therefore, fundamentally strong biotech stocks Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and United Therapeutics (UTHR) might be solid buys. These stocks are A (Strong Buy) rated in our proprietary…

StockNews.com

Regeneron Pharmaceuticals Unusual Options Activity

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange trades.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022

Upgrades

Benzinga

Regeneron Pharmaceuticals Whale Trades For October 03

Someone with a lot of money to spend has taken a bearish stance on Regeneron Pharmaceuticals (NASDAQ:REGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022

Upgrades

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Regeneron Pharmaceuticals Whale Trades For September 06

Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

What Are Whales Doing With Regeneron Pharmaceuticals

A whale with a lot of money to spend has taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange trades.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 25, 2022

Upgrades

Benzinga

What Are Whales Doing With Regeneron Pharmaceuticals

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

This Foreboding Sign Looms Over Regeneron Pharmaceuticals's Chart

If history is any guide, there may be trouble ahead for shares of Regeneron Pharmaceuticals (NASDAQ:REGN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

Benzinga

Here's How Much $1000 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 14.19% on an annualized basis producing an average annual return of 21.3%. Currently, Regeneron Pharmaceuticals has a market capitalization of $65.05 billion.

Benzinga

Regeneron Pharmaceuticals Whale Trades Spotted

Benzinga

If You Invested $1000 In This Stock 10 Years Ago, You Would Have $4,800 Today

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 6.25% on an annualized basis producing an average annual return of 17.08%. Currently, Regeneron Pharmaceuticals has a market capitalization of $61.64 billion.

Benzinga

Regeneron Pharmaceuticals Whale Trades Spotted

Benzinga

7 Analysts Have This to Say About Regeneron Pharmaceuticals

Over the past 3 months, 7 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule

The U.S. Food and Drug Administration (FDA) has approved Regeneron Pharmaceuticals, Inc.

1 2 3

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

416,812 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.